Lantern Pharma Inc. (LTRN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-1222.3%

-$7.18

vs $0.64 price

Levered DCF

-$6.80

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-22.94

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.93×	-0×	-2.91×	-4.61×	-7.06×	-20.26×	-38.33×	-53.39×
P/B	5.05×	1.62×	1.13×	1.17×	1.22×	6.08×	99.29×	-460.62×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-6.26×	-1.3×	-1.55×	-0×	-2.89×	-17.04×	-38.09×	-53.5×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	2.4×	5.83×	16.18×	20.99×	31.26×	36.64×	2.52×	0.68×
Debt / equity	12.02×	0.01×	0.01×	0×	0×	0.01×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-262.0%	-98.1%	-39.0%	-25446.9%	-17.3%	-30.0%	-257.4%	855.5%
Return on invested capital	-21.1%	-103.7%	-43.5%	-25731.0%	-17.5%	-29.8%	-257.4%	855.5%
Return on assets	-155.1%	-81.3%	-36.6%	-24236.6%	-16.7%	-29.0%	-169.5%	-383.8%
Free cash flow yield	-47.5%	-51.9%	-31.0%	-19.5%	-12.2%	-4.7%	-2.3%	-1.4%
Earnings yield	-51.8%	-60.5%	-34.4%	-21758.5%	-14.2%	-4.9%	-2.6%	-1.9%
Enterprise value	$107.1M	$27.1M	$24.7M	$28.4M	$35.7M	$100.6M	$92.4M	$92.5M
Net debt / EBITDA	-4.33×	0.35×	1.36×	0×	4.15×	3.24×	0.51×	0.26×
Cash conversion cycle (days)	0	0	-1,967	0	0	0	-107,300	14,007